Home / News / India News / Article /
Bharat Biotech gets nod for P-3 trials for intranasal booster jab
Updated On: 29 January, 2022 08:23 AM IST | New Delhi | Agencies
India is yet to approve the use of intranasal Covid-19 vaccine, BBV154, developed by the Covaxin maker; trial to be conducted at 5 sites
Listen to this article :
People without Aadhaar queue up for vaccine, in Howrah. Pic/PTI
India’s drug regulator has given permission to Bharat Biotech to conduct phase-3 clinical trial for its intranasal Covid vaccine as booster dose on participants who have been previously inoculated with SARS-CoV 2 vaccines. India is yet to approve the use of intranasal Covid-19 vaccine BBV154 developed by the Hyderabad-based company.
Drugs Controller General of India (DCGI) on January 27 gave the nod to Bharat Biotech to conduct phase-3 randomised multi-centric clinical study to evaluate immunogenecity and safety of its intranasal vaccine as booster dose on participants who have been previously vaccinated with Covid-19 vaccines approved under the New Drugs & Clinical Trials Rules, 2019. According to official sources, the trial would be conducted at five sites, including AIIMS Delhi.
Trending Stories
Latest Photos
Latest Videos
Latest Web Stories
ADVERTISEMENT
Mid-Day Fast
ADVERTISEMENT
ADVERTISEMENT